Makes sense.
It's a bit hard to draw conclusions regarding PFS from the data they've given us but obviously they've got a bit more data than us and know it's positive. As someone else mentioned too - only 3 or 4 of the 14 were on the 400mg dose that was ultimately chosen for 2a.
Market still staying away from this one until capital sorted out. I'm still expecting a cap raise reasonably soon.
Ann: Update on ACCENT Trial in Pancreatic Cancer, page-13
Add ATX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $16.02M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 814 | 5.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.0¢ | 99954 | 1 |
View Market Depth
| Last trade - 07.00am 21/05/2024 (20 minute delay) ? |
| ATX (ASX) Chart |
Day chart unavailable